Stockreport

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types [Yahoo! Finance]

NeoGenomics, Inc.  (NEO) 
Last neogenomics, inc. earnings: 4/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.neogenomics.com
PDF We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated FORT MYERS, Fla., February 25 [Read more]